viewScancell Holdings PLC

Scancell completes part 1 dosing for cancer study


Cancer drug developer Scancell (LON:SCLP) said it has completed patient dosing in part 1 of its on-going Phase 1/2 clinical trial for the SCIB1 ImmunoBody drug.

Five patients with metastatic tumours were given SCIB1, with doses of 8mg. There were no reported serious adverse events.

Scancell said that immunology and clinical responses are currently being analysed, and will be reported to the market by the end of the second quarter.

Previously patients given lower dosage, 4mg, showed an immune response that might be associated with clinical benefit in patients with malignant melanoma.

Scancell also has permission to expand the second part of the study to include up to 13 patients, receiving 8mg. And with the absence of any serious toxicity in part 1, new patients are being recruited for this stage of the study.

The first patient of the part 2 cohort was dosed with SCIB1 earlier this week.

"Our higher dose 8mg SCIB1 study is progressing well,” said joint chief executive Richard Goodfellow.

“In view of the continued safety profile of SCIB1 at the higher dose, we are now recruiting for Part 2 of this cohort, which will assess the immune and clinical response to SCIB1 in a larger number of patients with Stage III/IV melanoma.

“We look forward to reporting the results from Part 1 of the study later this year."

Quick facts: Scancell Holdings PLC

Price: 5.1 GBX

Market: LSE
Market Cap: £23.73 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...



Richard Goodfellow Presents on Behalf of Scancell at the Biotech Capital...

Richard Goodfellow Presents on Behalf of Scancell at the Biotech Capital Conference 

on 03/08/2016

2 min read